With budgets rising and sales flattening, have we reached a tipping point? This paper by ATKearney outlines the choice that drug companies face—whether to play in ever-smaller niches or reassert their position as key partners in improving global healthcare outcomes—as well as how they can transform themselves. To read, click here.